HilleVax Acquired by XOMA, Delisting from Nasdaq

HilleVax, Inc. has been acquired by XOMA Royalty Corporation, completing the merger on September 17, 2025. Following the acquisition, HilleVax will be delisted from Nasdaq and cease its registration under the Securities Exchange Act. The latest analyst rating for HLVX stock is a Hold with a $2.00 price target, while Spark's AI Analyst rates it as Underperform due to financial instability and reliance on external funding. HilleVax's current market cap is $105.3M, with significant risks noted in its stock performance.

Hillevax Inc. Announces Regulatory Changes as Nasdaq Suspends Trading and Delists Shares Following Merger Completion

Hillevax Inc. has announced that following its merger with XOMA Royalty Corporation, it will become a wholly-owned subsidiary of XOMA. As a result, Nasdaq will file Form 25, leading to the suspension of Hillevax shares from trading effective September 17, 2025. Hillevax will also file Form 15 to terminate its registration and suspend reporting obligations. This marks a significant regulatory change in Hillevax's corporate structure.

XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

XOMA Royalty closes tender offer for HilleVax.

18:34 ET $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of HilleVax, Inc. (NASDAQ: HLVX)

Class Action Attorney Juan Monteverde of Monteverde & Associates PC is investigating HilleVax, Inc. (NASDAQ: HLVX) regarding its proposed sale to XOMA Royalty Corporation. Under the deal, HilleVax shareholders will receive $1.95 per share in cash and a contingent value right for potential additional payments. The firm, recognized for recovering millions for shareholders, invites concerned stockholders to seek more information without obligation.

HilleVax | 10-Q: FY2025 Q2 EPS Beats Estimate at USD -0.11